目的 探討烏司他丁注射液聯(lián)合燈盞花素注射液治療病毒性心肌炎的臨床療效。方法 選取2016年3月-2017年7月上海市浦東醫(yī)院收治的病毒性心肌炎患者86例為研究對象，所有患者采用Excel表法隨機(jī)分為對照組和治療組，每組各43例。對照組靜脈滴注燈盞花素注射液，10 mg加入到5%葡萄糖注射液250 mL中，1次/d。治療組在對照組的基礎(chǔ)上靜脈滴注烏司他丁注射液，20萬單位加入到0.9%氯化鈉注射液100 mL中，2次/d。兩組患者均持續(xù)治療14 d。觀察兩組的臨床療效，比較兩組的心臟損傷標(biāo)志物水平和血清炎癥因子水平。結(jié)果 治療后，對照組和治療組的總有效率分別為81.4%、93.0%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）、天門冬氨酸氨基轉(zhuǎn)移酶（AST）、心肌肌鈣蛋白I（cTnI）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些心臟損傷標(biāo)志物水平明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-6（IL-6）水平顯著下降，超氧化物歧化酶（SOD）水平顯著升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些血清炎癥因子水平明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 烏司他丁注射液聯(lián)合燈盞花素注射液治療病毒性心肌炎具有較好的臨床療效，可改善心臟損傷，降低炎癥水平，增強(qiáng)心肌功能，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Ulinastatin Injection combined with Breviscapine Injection in treatment of viral myocarditis. Methods Patients (86 cases) with viral myocarditis in Shanghai Pudong Hospital from March 2016 to July 2017 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were iv administered with Breviscapine Injection, 10 mg added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were iv administered with Ulinastatin Injection on the basis of the control group, 200 000 U added into normal saline 100 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the levels of cardiac damage markers and serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.4% and 93.0%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of CK, CK-MB, AST, and cTnI in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And levels of cardiac damage markers in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of TNF-α and IL-6 in two groups were significantly decreased, but the levels of SOD in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And serum inflammatory factors in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Ulinastatin Injection combined with Breviscapine Injection has clinical curative effect in treatment of viral myocarditis, can improve cardiac damage, decrease inflammation level, and enhance myocardial function, which has a certain clinical application value.